The Complete® Self-Expanding Stent and Stent Delivery System Registry

Peripheral Vascular Disease Clinical Trial

Official title:

The Medtronic Complete® Self-Expanding Stent and Stent Delivery System Registry: a Non-randomized Prospective, Multicenter, Consecutive Registry

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00730730
• Other study ID #: IP084
• Secondary ID: IDE G070114
• Status: Completed
• Phase: N/A
• First received: August 5, 2008
• Last updated: January 28, 2016
• Start date: November 2007
• Est. completion date: August 2012

Study information

• Verified date: January 2016
• Source: Medtronic Endovascular
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to show if a new delivery system with a modified stent is safe in treating occluded iliac arteries in patients with peripheral vascular disease. The modified Complete SE delivery system is hypothesized to assist physicians with more accurate stent placement reducing the likelihood of stent 'jumping' seen with the use of many self-expanding stent systems.

Description:

The study is being conducted to collect the 30-day safety data on the stent delivery system for all subjects enrolled into the study (with a minimum of 50 subjects enrolled) as well as the long-term 9-month safety and efficacy data on all subjects enrolled (with a minimum of 10 subjects enrolled into the study having the 120mm length stent implanted).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: August 2012
• Est. primary completion date: February 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The lesion(s) is either de-novo or restenotic in nature, located in either the common iliac artery or the external iliac artery and is >50% stenosed

• Target vessel reference diameter = 4.5 mm and = 9.5 and can accommodate stent diameters of 6.0 - 10.0mm

• Subject is either asymptomatic with a lesion stenosis =70% or symptomatic with a lesion stenosis =50% with an Ankle Brachial Index (ABI) < 0.90 or Toe Brachial Index (TBI) <0.80 or an abnormal Pulse Volume Recording (PVR);

• Total lesion length is < 110 mm;

Exclusion Criteria:

• Excessive Peripheral Vascular Disease (PVD), unresolved fresh thrombus or tortuosity or a target lesion/vessel that is heavily calcified ;

• Tissue loss in the extremity: category 5 or 6 on the Rutherford scale;

• Target lesion has a previous stent, or is within a prosthetic vascular bypass graft or within 1 cm of a graft anastomosis;

• Target lesion is within an aneurysm or associated with an aneurysm in the vessel segment proximal or distal to the target lesion;

• Lesion requires treatment with a non-standard device associated with Percutaneous Transluminal Angioplasty (PTA) prior to stent placement;

• Inadequate distal run-off;

• Planned interventional procedure or vascular surgery to target vessel within 30 days pre- or post-index iliac procedure;

• History of bleeding diatheses or coagulopathy or will refuse blood transfusions;

• Platelet count <50,000 cells/mm3 or >700,000 cells/mm3, or White Blood Count (WBC) <3,000 cells/mm3;

• Creatinine >2.0 mg/dl;

• Participation in another investigational device or drug study and has not completed the primary endpoint(s) follow-up phase of that study at least 30 days prior to enrollment in this trial or the subject has previously been enrolled in this Registry;

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Peripheral Arterial Disease
• Peripheral Vascular Disease
• Peripheral Vascular Diseases
• Vascular Diseases

Intervention

Device:
• Complete SE Iliac Stent
Iliac stenting
• Complete SE Iliac Stent
Self-expanding stent

Locations

Country	Name	City	State
United States	Michigan Vascular Research Center	Flint	Michigan
United States	New York Presbyterian Hospital, Columbia Campus	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Medtronic Endovascular	Medtronic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Participants With Major Adverse Events (MAE)	Major adverse events (MAE) defined as any death, target limb loss or clinically-driven Target Lesion Revascularization (TLR)/Target Vessel Revascularization (TVR) with percutaneous transluminal angioplasty or aorto-iliac bypass graft) for all subjects enrolled into the registry	30 days	Yes
Secondary	Number of Participants With Acute Success	angiographic evidence of < 30 % final residual stenosis of the target lesion after stent placement with no occurrence of a device- related, procedure-related MAE or vascular event (stent thrombosis, major bleeding complications)	from after stent placement to prior to hospital discharge (up to 3 days)	Yes
Secondary	Number of Limbs With Improvement Using Rutherford Scale to Determine Clinical Success.	Improvement of Rutherford scale by = 1 category between pre-procedure (Baseline) and 30-day follow-up-; Category 0: Asymptomatic, no hemodynamically significant occlusive disease; Category 1: Mild claudication; Category 2: Moderate claudication; Category 3: Severe claudication; Category 4: Ischemic rest pain; Category 5: Minor tissue loss; non-healing ulcer; focal gangrene with diffuse pedal ischemia; Category 6: Major tissue loss extending above transmetatarsal level;functional foot no longer salvageable	From baseline up to 30-days	Yes
Secondary	Number of Limbs With Improvement Using Ankle-brachial Index and Toe Brachial Index to Determine Hemodynamic Success.	Improvement in ankle-brachial index (ABI) or toe-brachial index (TBI) > 0.10 over pre-procedure level OR deterioration by = 0.15 from first post-procedure exam OR pulse volume recording (PVR) distal to the target lesion treated maintained at = 5 mm above pre-procedure tracing for those subjects with no pre-procedure ABI/TBI.; An ABI = 0.90 is considered normal.	From baseline up to 30-days	No